Bellmunt Risk Score as prognostic tool in metastatic castration-resistant prostate cancer: post hoc analysis of two phase 3 studies

Metastatic castration-resistant prostate cancer (mCRPC) is an uncurable disease with a highly variable clinical course, necessitatin robust prognostic tools to guide individualized patient management. Pooled analysis of two multinational phase 3 studies (ACIS in first-line setting and ELM-PC-5 in postdocetaxel setting) evaluated the Bellmunt Risk Score (BRS) as prognostic tool for overall survival and radiographic progression-free survival in men with mCRPC. Among 1756 patients in the analysis, having a higher BRS was consistently associated with unfavorable overall survival as well as unfavorable radiographic progression-free survival. In multivariable models, the BRS remained a robust and independent prognostic factor for both outcomes. The authors conclude that these findings suggest that the BRS provides clinically meaningful prognostic information that can aid in guiding treament decisions among patients with mCRPC.